SkinBioTherapeutics (GB:SBTX) has released an update.
SkinBioTherapeutics PLC, a life science company specializing in skin health, has secured an investment of £1.56 million from Premier Miton and Cynosure Capital, reaffirming financial stability through Q1 2025 without actively seeking additional funds. This strategic move bolsters the company’s balance sheet, supporting ongoing projects such as AxisBiotix-Ps and potential acquisitions, while negating the need for further share authorization before the next Annual General Meeting.
For further insights into GB:SBTX stock, check out TipRanks’ Stock Analysis page.
